Skip to main content
. 2022 Oct 25;15:152. doi: 10.1186/s13045-022-01375-4

Table 3.

ORR in KRAS G12C NSCLC by STK11 and KEAP1 mutation status from single arm phase II studies of sotorasib (CodeBreaK100 [94]) and adagrasib (KRYSTAL-1 [100])

Overall (%) STK11mt, KEAP1wt (%) STK11mt, KEAP1mt (%) STK11wt, KEAP1mt (%)
Sotorasib 920 mg daily 37.1 50 23 14
Adagrasib 600 mg bid 42.9 44.0 35.7 14.3